Last reviewed · How we verify
Y-3 for injection
Y-3 for injection is a monoclonal antibody that targets the PD-1 receptor.
Y-3 for injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Y-3 for injection |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, Y-3 for injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and an anti-tumor immune response. This results in the killing of cancer cells and the slowing of tumor growth.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pneumonitis
Key clinical trials
- A Phase 1 Study of Y-3 in US Healthy Volunteers. (PHASE1)
- Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants (PHASE1)
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (PHASE3)
- Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects (PHASE1)
- The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction (NA)
- Y-3 for Injection in the Treatment of Acute Ischemic Stroke (PHASE3)
- Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial (PHASE2)
- Y-3 Injection Through Skull Bone Marrow in the Treatment of Acute Malignant Middle Cerebral Artery Infarction (SOLUTION) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y-3 for injection CI brief — competitive landscape report
- Y-3 for injection updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI